Evidence map›Paper›PMID 41158043›Full record

SynthesisZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC].

Yuling Zhong, Jingyi Wang, Lin Wu

Abstract readSystematic ReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuling ZhongThe Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School 
of Medicine, Central South University, Changsha 410013, China.
Jingyi WangThe Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School 
of Medicine, Central South University, Changsha 410013, China.
Lin WuThe Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School 
of Medicine, Central South University, Changsha 410013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in targeted therapy and immunotherapy have significantly improved clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC), reshaping treatment paradigms. However, most patients ultimately face drug resistance, with limited options for subsequent therapies and suboptimal treatment efficacy, presenting a prominent challenge in current clinical practice. Antibody-drug conjugates (ADCs), characterized by high efficacy and favorable safety profiles, have emerged as a promising therapeutic frontier in recent years. This systematic review provides a comprehensive overview of the latest advancements in ADCs-based therapies for lung cancer, alongside discussions of the prevailing challenges in this rapidly evolving domain.
.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungImmunoconjugatesLung NeoplasmsHumansImmunotherapyAntineoplastic AgentsImmunoconjugatesAntibody-drug conjugatesBiomarkerLung neoplasmsToxic reactions

Identifiers

PMID41158043
PMCPMC12580394

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.